A Phase 2/3 multicenter, randomized, open-label study of lenalidomide vs investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma.
Authors
Czuczman, MTrněný, M
Davies, A
Rule, S
Linton, Kim M
Wagner-Johnston, N
Gascoyne, R
Slack, G
Brousset, P
Eberhard, D
Hernandez-Ilizaliturri, F
Salles, G
Witzig, T
Zinzani, Pier L
Wright, G
Staudt, L
Yang, Y
Williams, P
Lih, C
Russo, J
Thakurta, A
Hagner, P
Fustier, P
Song, D
Lewis, I
Affiliation
Charles University HospitalCancer Research UK Centre, Somers Cancer Research Building, University of SouthamptonIssue Date
2017-04-05
Metadata
Show full item recordAbstract
Randomized, multicenter, open-label, phase 2/3 trial investigating lenalidomide versus investigator's choice (IC) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).Citation
A Phase 2/3 multicenter, randomized, open-label study of lenalidomide vs investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma.. 2017 Clin Cancer ResJournal
Clinical Cancer ResearchDOI
10.1158/1078-0432.CCR-16-2818PubMed ID
28381416Type
ArticleLanguage
enISSN
1078-0432ae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.CCR-16-2818
Scopus Count
Collections
Related articles
- Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
- Authors: Mondello P, Steiner N, Willenbacher W, Ferrero S, Ghione P, Marabese A, Pitini V, Cuzzocrea S, Mian M
- Issue date: 2016 Sep
- Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
- Authors: Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE
- Issue date: 2015 Jan 20
- Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
- Authors: Trněný M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva J, Rule S, Afanasyev B, Kaplanov K, Thyss A, Kuzmin A, Voloshin S, Kuliczkowski K, Giza A, Milpied N, Stelitano C, Marks R, Trümper L, Biyukov T, Patturajan M, Bravo MC, Arcaini L, SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network
- Issue date: 2016 Mar
- Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
- Authors: Goy A, Ramchandren R, Ghosh N, Munoz J, Morgan DS, Dang NH, Knapp M, Delioukina M, Kingsley E, Ping J, Beaupre DM, Neuenburg JK, Ruan J
- Issue date: 2019 Sep 26
- Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.
- Authors: Abramson JS, Ku M, Hertzberg M, Huang HQ, Fox CP, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Townsend W, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Simko S, Orellana-Noia V, Ta R, Relf J, Dixon M, Kallemeijn M, Mulvihill E, Huang H, Lundberg L, Gregory GP
- Issue date: 2024 Nov 16